Full Press Release Details
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1 2 Tissue Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations.
IDYA
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1 2 Tissue Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
Key Takeaway: IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1 2 Tissue Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations